This research demonstrates functional correction of β-thalassemic stem cells, suggesting a promising therapeutic approach.
Duplex BE targeting both BCL11A erythroid enhancer and HBG promoter enables functional correction and genome integrity. Our study highlights the efficacy, safety, and therapeutic potential of the present duplex BE approach.
No takes yet. Share an insight, caveat, or question.
Papaioannou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: